INCIVEK
LOE ApproachingNDAORALTABLETPriority Review
Approved
May 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INCIVEK is an oral small-molecule antiviral approved in 2011 for hepatitis C virus (HCV) treatment. The drug is a protease inhibitor that blocks viral replication. It represents a significant advance in HCV therapy but is now facing loss of exclusivity.
LOE Approaching1.8 years to LOE
Competitive pressure remains moderate at 15, but the product is in late-stage lifecycle with minimal current job openings, indicating a contracting commercial footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on INCIVEK at Vertex Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.